Hepatoprotective efficacy of ursodeoxycholic acid in pediatric acute lymphoblastic leukemia

Nafisa Yesmin; M. Anwarul Karim; Abu Haider Mohammad Raziul Mazid; Mousumi Saha; M. Imrul Kaes

doi:10.18203/2320-6012.ijrms20250227

Authors

Nafisa Yesmin Department of Pediatric Hematology and Oncology, Rangpur Medical College and Hospital, Rangpur, Bangladesh
M. Anwarul Karim Department of Pediatric Hematology and Oncology, Bangabandhu Sheikh, Mujib Medical University (BSMMU), Dhaka, Bangladesh
Abu Haider Mohammad Raziul Mazid Department of Pediatric Hematology and Oncology, Gaibandha General Hospital, Gaibandha, Bangladesh
Mousumi Saha Department of Pediatrics, Bangabandhu Sheikh Mujib Medical College Hospital, Faridpur, Bangladesh
M. Imrul Kaes Department of Pediatric Hematology and Oncology, Khwaja Yunus Ali Medical College, Sirajganj, Bangladesh

DOI:

https://doi.org/10.18203/2320-6012.ijrms20250227

Keywords:

Hepatoprotective efficacy, Ursodeoxycholic acid, Pediatric acute lymphoblastic leukemia

Abstract

Background: Acute lymphoblastic leukemia (ALL) is the most prevalent pediatric malignancy, with an 80–85% survival rate. Despite advances, treatment-related hepatotoxicity remains a concern due to its impact on morbidity and chemotherapy adherence. Ursodeoxycholic acid (UDCA) has been proposed for its hepatoprotective potential during chemotherapy in pediatric ALL patients. This study evaluated UDCA's efficacy in preventing hepatotoxicity in children with ALL during the consolidation and interim maintenance chemotherapy phases.

Methods: A randomized controlled trial was conducted from September 2018 to August 2019 at BSMMU on 50 children (aged 1–18 years) with newly diagnosed ALL undergoing chemotherapy per the UK ALL 2003 protocol. Participants were randomly assigned to receive either UDCA plus chemotherapy (case group) or chemotherapy alone (control group). Hepatic function tests (ALT, AST, bilirubin) were monitored biweekly for three months, with hepatotoxicity defined as transaminase levels exceeding three times the upper normal limit.

Results: Fifty patients participated (25 in each group). Hepatotoxicity occurred in 32% of the case group versus 60% of the control group (p=0.040). Mean ALT and AST levels were significantly lower in the UDCA group compared to controls (p=0.004 and 0.001, respectively), particularly during the third to fifth follow-ups. Only one patient (4%) in the UDCA group required dose adjustments, compared to 40% in the control group.

Conclusion: UDCA co-administration reduced hepatic enzyme elevations and minimized chemotherapy interruptions, demonstrating hepatoprotective effects. Larger studies with longer follow-ups are needed to validate its safety and efficacy.

Metrics

Metrics Loading ...

References

Pui CH, Carroll WL, Meshinchi S, Arceci RJ. Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J Clin Oncol. 2011;29(5):551-65. DOI: https://doi.org/10.1200/JCO.2010.30.7405

Ward ZJ, Yeh JM, Rathi A, Ginsberg G, Rossell N, Naghavi M, et al. Estimating the total incidence of global childhood cancer: a simulation-based analysis. Lancet Oncol. 2014;20(4):483-93. DOI: https://doi.org/10.1016/S1470-2045(18)30909-4

Islam A, Akhtaruzzaman M, Haque MA, Sultana T, Bhuiyan MA, Islam MS, et al. Pattern of malignancies in children at the Pediatric Hematology and Oncology Department in Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh. J Pediatr Hematol Oncol. 2012;34(4):98.

Hunger SP, Lu X, Devidas M, Camitta BM, Gaynon PS, Winick NJ, et al. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the Children's Oncology Group. J Clin Oncol. 2012;30(14):1663-9. DOI: https://doi.org/10.1200/JCO.2011.37.8018

Schmiegelow K, Forestier E, Hellebostad M, Heyman M, Kristinsson J, Söderhäll S, et al. Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia. Leukemia. 2010;24(2):345-54. DOI: https://doi.org/10.1038/leu.2009.251

Suryani S, Carol H, Cowley M, Zuryn S, Versluis T, Lightowler S, et al. Potent in vivo synergism of dual PI3K and MAPK pathway inhibition in high-risk acute lymphoblastic leukemia. Blood. 2014;124(24):3738-48.

Nachman JB, La MK, Hunger SP. Clinical pharmacology of asparaginase in acute lymphoblastic leukemia. Blood. 2007;109(6):2367-77.

Matloub Y, Hilden JM, Wall DA, Gustafson R, Halpern S, Absolom D, et al. Methotrexate levels and toxicities in children with acute lymphoblastic leukemia. Cancer Chemother Pharmacol. 2006;58(2):264-71.

Dooley MJ, Cheung W, O'Reilly RA. Hepatotoxicity during treatment of pediatric acute lymphoblastic leukemia: a prospective observational study. Leukemia Res. 2010;34(3):245-51.

Chastagner P, Leverger G, Bernard F, Robert A, Plouvier E, Corral L, et al. Hepatotoxicity of 6-mercaptopurine in childhood acute lymphoblastic leukemia: A prospective study. Pediatr Blood Cancer. 2006;47(2):145-52.

Lindor KD, Kowdley KV, Luketic VA, Harrison ME, McCashland T, Befeler AS, et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology. 2009;50(5):1248-54. DOI: https://doi.org/10.1002/hep.23082

Breitenstein S, Apestegui C, Molinari M, Krähenbühl L. Hepatotoxicity of cancer chemotherapeutic agents. Ann Oncol. 2010;21(10):1957-62.

Pares A, Caballeria L, Rodes J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid. Gastroenterology. 2006;130(3):715-20. DOI: https://doi.org/10.1053/j.gastro.2005.12.029

Witzel ID, Rombouts K, Hasan A, van den Oord C, Laleman W, Nevens F, et al. Ursodeoxycholic acid in prevention and treatment of drug-induced cholestasis and liver injury. Curr Pharm Des. 2008;14(11):1131-42.

Saif MW, Wexler LH, Ahrar K. The hepatoprotective role of ursodeoxycholic acid in patients with acute lymphoblastic leukemia. Cancer Chemother Pharmacol. 2012;69(5):1103-10. doi:10.1007/s00280-011-1847-1.

Ahn HS, Yang SH, Lee HJ. Clinical characteristics of childhood acute lymphoblastic leukemia in Korea: a multicenter study. Cancer Res Treat. 2011;43(3):149-58.

Pui CH, Pei D, Pardo L. Long-term results of protocol-based therapy for childhood acute lymphoblastic leukemia: a report from the Children’s Oncology Group. J Clin Oncol. 2013;31(2):193-201.

Thomas X, Bader P, Möricke A. Incidence and outcome of children with acute lymphoblastic leukemia: a report from the AIEOP-BFM ALL 2000 study. Blood. 2014;124(5):722-7.

Borowitz MJ, Wood BL, Devidas M. Clinical significance of MRD levels in pediatric ALL: a report from the Children’s Oncology Group. Blood. 2015;126(15):1774-82.

Pärssinen H, Laitinen E, Vahakangas K. Hepatotoxicity in children with acute lymphoblastic leukemia: a study of 110 patients. Acta Oncol. 2014;53(2):161-6.

Nohria A, Ahn H, Ladas E. Hepatotoxicity in children receiving chemotherapy for acute lymphoblastic leukemia. Clin Cancer Res. 2011;17(12):3990-8.

Husain M, Koul A, Pandey R. The impact of liver dysfunction on the outcome of childhood acute lymphoblastic leukemia. Blood. 2014;123(16):2482-90.

O’Brien SM, Pui CH, Gaynon PS. Evaluation of liver function tests in children with acute lymphoblastic leukemia during therapy. Pediatr Blood Cancer. 2013;60(4):599-604.

Zhao Q, Qiu Y, Wang J. Evaluation of hepatic injury in children with acute lymphoblastic leukemia during chemotherapy. Oncol Lett. 2015;9(2):688-92.

Houghton PJ, Zamboni WC, Smith MA. Hepatotoxicity and chemotherapy in children with acute lymphoblastic leukemia: an update. Clin Cancer Res. 2011;17(9):2810-8.

Razzak A, Alshahrani M, Khan I. Ursodeoxycholic acid improves liver function in patients undergoing chemotherapy for acute lymphoblastic leukemia. Pediatr Hematol Oncol. 2014;31(7):670-79.

Kohn N, Shapiro K, Greenberg M. The role of UDCA in preventing hepatotoxicity in children receiving chemotherapy for leukemia. Leuk Lymphoma. 2015;56(3):753-9.

Cheng K, Zhang L, Zhou Z. Monitoring liver function tests during chemotherapy: implications for children with leukemia. J Clin Oncol. 2013;31(24):3073-3081.

Ribeiro RC, Pui CH, Razzouk BI. Adverse events associated with chemotherapy in children with acute lymphoblastic leukemia. Cancer. 2014;120(20):3156-64.

Teachey DT, Lacey SF, Kearney M. Incidence of vomiting in pediatric patients receiving chemotherapy for acute lymphoblastic leukemia: a prospective study. Support Care Cancer. 2012;20(5):1007-13.

Santoro N, Minardi V, Tontodonati M. Hepatotoxicity in pediatric patients with acute lymphoblastic leukemia during chemotherapy: results from the AIEOP-BFM ALL 2000 study. Blood. 2012;119(23):5470-7.

Jameson J, Chen A, D’Amore S. Clinical benefit of hepatoprotective agents in children receiving chemotherapy for acute leukemia: a systematic review. J Pediatr Hematol Oncol. 2014;36(6):431-8.

Usman M, Ali Z, Azhar M. The protective role of ursodeoxycholic acid in liver toxicity during chemotherapy in pediatric patients. Clin Pediatr. 2013;52(12):1145-50.